Skip to main content
Fig. 2 | Head & Face Medicine

Fig. 2

From: Imaging predictor of ophthalmic involvement in maxillary sinus cancer during super selective intra-arterial cisplatin infusion and concomitant radiotherapy (RADPLAT)

Fig. 2

Overall survival. OS curve showing median OS of 173.2 (127.8–218.6 weeks; 95 % CI) weeks in Non-ophthalmic involvement group and 226.2 (189.4–263.0 weeks ; 95 % CI) weeks in Ophthalmic involvement group without significant difference (p = 0.35). Local progressive free survival. LPFS curve showing median LPFS of 182.0 (132.4–231.6 weeks; 95 % CI) weeks in Non-ophthalmic involvement group and 203.1 (149.9–256.3 weeks; 95 % CI) weeks in Ophthalmic involvement group without significant difference (p = 0.93)

Back to article page

Head & Face Medicine

ISSN: 1746-160X

Contact us